CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. Here we present the analysis of CD200 expression in human Multiple Myeloma (MM) samples. We found that CD200-positive cells express ERK and p-ERK. Moreover, UO126, a MEK inhibitor, reduces CD200 expression. Furthermore, we observe that CD200-positive cells show reduced immunogenicity compared to normal lymphocytes and that such immunogenicity increases when UO126 is used. We therefore hypothesize that CD200 expression in MM could suppress antitumor response and that anti-CD200 treatment might be therapeutically beneficial in CD200-expressing tumors.
|Titolo:||CD200 expression in patients with multiple myeloma: Another piece of the puzzle|
|Data di pubblicazione:||2013|
|Citazione:||CD200 expression in patients with multiple myeloma: Another piece of the puzzle / Conticello C; Giuffrida R; Parrinello N; Buccheri N; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 37:12(2013), pp. 1616-1621.|
|Appare nelle tipologie:||1.1 Articolo in rivista|